UK Markets close in 3 hrs 38 mins

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.7270+0.0170 (+2.39%)
At close: 03:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.54
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 31.7700
52-week low 30.5160
50-day moving average 30.8269
200-day moving average 30.8481

Share statistics

Avg vol (3-month) 356.6k
Avg vol (10-day) 345k
Shares outstanding 537.94M
Implied shares outstanding 6N/A
Float 818.45M
% held by insiders 143.47%
% held by institutions 117.96%
Shares short (28 Apr 2022) 4325.1k
Short ratio (28 Apr 2022) 44.94
Short % of float (28 Apr 2022) 41.52%
Short % of shares outstanding (28 Apr 2022) 40.86%
Shares short (prior month 30 Mar 2022) 4394.9k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 215:16
Last split date 305 May 2015

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-5,582.64%

Management effectiveness

Return on assets (ttm)-141.95%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)144k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-82.90%
Gross profit (ttm)125k
EBITDA -7.91M
Net income avi to common (ttm)-8.58M
Diluted EPS (ttm)-0.2370
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)584k
Total cash per share (mrq)0.01
Total debt (mrq)13.2M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.25
Book value per share (mrq)-0.26

Cash flow statement

Operating cash flow (ttm)-7.86M
Levered free cash flow (ttm)-4.49M